HeartBeam Inc. (NASDAQ: BEAT) announced the launch of a pilot study focused on evaluating its on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia. This development addresses the growing seriousness of coronary artery disease as populations age and cardiovascular risk factors become more prevalent.
The study represents a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets. According to the company, ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time. HeartBeam's patch is designed to change that by generating an on-demand 12-lead ECG, offering a new tool for earlier identification of high-risk patients.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. Healthcare providers are seeking faster and more accessible ways to identify high-risk patients earlier, and HeartBeam's technology aims to meet this need.
For more information, visit https://nnw.fm/BEAT.
